{"id":56896,"date":"2026-02-11T22:01:05","date_gmt":"2026-02-11T14:01:05","guid":{"rendered":"https:\/\/flcube.com\/?p=56896"},"modified":"2026-02-11T22:01:06","modified_gmt":"2026-02-11T14:01:06","slug":"fda-cracks-down-on-compounded-glp-1-apis-novo-nordisk-sues-hims-hers-for-patent-infringement","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56896","title":{"rendered":"FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement"},"content":{"rendered":"\n

The U.S. Food and Drug Administration (FDA)<\/strong> announced decisive regulatory action<\/strong> to restrict GLP-1 active pharmaceutical ingredients (APIs)<\/strong> used in non-FDA-approved compounded drugs<\/strong>, targeting mass-marketed alternatives<\/strong> to Wegovy and Ozempic<\/strong> by Hims & Hers and other compounding pharmacies<\/strong>. Concurrently, Novo Nordisk<\/strong> (NYSE:\u202fNVO<\/a><\/strong>) filed patent infringement litigation<\/strong> against Hims & Hers<\/strong>, alleging unauthorized compounded semaglutide products<\/strong> violate U.S. Patent 8,129,343<\/strong> and mislead consumers<\/strong> regarding clinical benefits and safety<\/strong>.<\/p>\n\n\n\n

Regulatory Enforcement Framework<\/h2>\n\n\n\n
Agency Action<\/th>Target<\/th>Enforcement Tools<\/th><\/tr><\/thead>
API Restrictions<\/strong><\/td>GLP-1 APIs for non-FDA-approved compounded drugs<\/td>Import restrictions; supply chain interdiction<\/td><\/tr>
Mass Marketing Prohibition<\/strong><\/td>Hims & Hers and compounding pharmacies promoting “similar alternatives”<\/td>Cease-and-desist orders; platform removal<\/td><\/tr>
Advertising Crackdown<\/strong><\/td>Misleading direct-to-consumer claims<\/td>Warning letters; fines; criminal referral<\/td><\/tr>
Compliance Measures<\/strong><\/td>Unapproved compounded GLP-1 products<\/td>Seizure and injunction<\/strong> authority<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Novo Nordisk Litigation<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Plaintiff<\/strong><\/td>Novo Nordisk A\/S (NYSE:\u202fNVO)<\/td><\/tr>
Defendant<\/strong><\/td>Hims & Hers Health, Inc.<\/td><\/tr>
Allegation<\/strong><\/td>Patent infringement; false\/misleading marketing<\/td><\/tr>
Patent<\/strong><\/td>U.S. Patent 8,129,343 (semaglutide formulation)<\/td><\/tr>
Product<\/strong><\/td>“Compounded GLP-1 Pill” (compounded semaglutide)<\/td><\/tr>
Claims<\/strong><\/td>Consumer deception<\/strong> regarding clinical benefits and safety; market flooding<\/strong> with knock-off Wegovy\/Ozempic<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Implications<\/h2>\n\n\n\n
Factor<\/th>Industry Impact<\/th><\/tr><\/thead>
GLP-1 Supply-Demand Imbalance<\/strong><\/td>Novo Nordisk and Eli Lilly shortages<\/strong> (2023-2024) created gray market opportunity<\/strong> for compounders; FDA action restores regulated channel integrity<\/strong><\/td><\/tr>
Patient Safety Risks<\/strong><\/td>Compounded GLP-1 products lack FDA purity, potency, and sterility verification<\/strong>; reported adverse events include dosing errors and contamination<\/strong><\/td><\/tr>
Novo Nordisk IP Defense<\/strong><\/td>Patent litigation protects $15+ billion Wegovy\/Ozempic franchise<\/strong>; signals aggressive enforcement<\/strong> against compounding and telehealth circumvention<\/td><\/tr>
Telehealth Regulatory Scrutiny<\/strong><\/td>Hims & Hers direct-to-consumer model<\/strong> faces dual FDA\/Novo pressure<\/strong>; potential business model restructuring<\/strong> required<\/td><\/tr>
Compounding Pharmacy Impact<\/strong><\/td>503A\/503B facility compliance costs<\/strong> escalate; mass-market GLP-1 compounding<\/strong> economically unviable post-enforcement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Competitive Dynamics & Industry Response<\/h2>\n\n\n\n
Stakeholder<\/th>Strategic Positioning<\/th><\/tr><\/thead>
Novo Nordisk<\/strong><\/td>Supply chain control<\/strong> via API restrictions; patent litigation<\/strong> deters future infringers; brand integrity<\/strong> protection<\/td><\/tr>
Eli Lilly<\/strong><\/td>Mounjaro\/Zepbound<\/strong> benefit from competitor compounding elimination<\/strong>; aligned FDA enforcement interests<\/td><\/tr>
Hims & Hers<\/strong><\/td>Revenue risk<\/strong> from GLP-1 product line termination; pivot to licensed therapies<\/strong> or settlement negotiations<\/strong><\/td><\/tr>
Traditional Compounding<\/strong><\/td>Legitimate 503A patient-specific compounding<\/strong> preserved; mass-market operations<\/strong> curtailed<\/td><\/tr>
FDA<\/strong><\/td>Public health protection<\/strong> priority; enforcement precedent<\/strong> for future drug shortage exploitation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding FDA enforcement action effectiveness, Novo Nordisk litigation outcomes, and GLP-1 market supply stabilization. Actual results may differ due to legal proceeding timelines, compounding pharmacy compliance responses, and potential congressional intervention on drug pricing and access.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The U.S. Food and Drug Administration (FDA) announced decisive regulatory action to restrict GLP-1 active…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[4361,148,860],"class_list":["post-56896","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-hot-targets","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"\nFDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration (FDA) announced decisive regulatory action to restrict GLP-1 active pharmaceutical ingredients (APIs) used in non-FDA-approved compounded drugs, targeting mass-marketed alternatives to Wegovy and Ozempic by Hims & Hers and other compounding pharmacies. Concurrently, Novo Nordisk (NYSE:\u202fNVO) filed patent infringement litigation against Hims & Hers, alleging unauthorized compounded semaglutide products violate U.S. Patent 8,129,343 and mislead consumers regarding clinical benefits and safety.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56896\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration (FDA) announced decisive regulatory action to restrict GLP-1 active pharmaceutical ingredients (APIs) used in non-FDA-approved compounded drugs, targeting mass-marketed alternatives to Wegovy and Ozempic by Hims & Hers and other compounding pharmacies. Concurrently, Novo Nordisk (NYSE:\u202fNVO) filed patent infringement litigation against Hims & Hers, alleging unauthorized compounded semaglutide products violate U.S. Patent 8,129,343 and mislead consumers regarding clinical benefits and safety.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56896\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-11T14:01:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T14:01:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56896#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56896\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement\",\"datePublished\":\"2026-02-11T14:01:05+00:00\",\"dateModified\":\"2026-02-11T14:01:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56896\"},\"wordCount\":420,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Hot targets\",\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56896#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56896\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56896\",\"name\":\"FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-11T14:01:05+00:00\",\"dateModified\":\"2026-02-11T14:01:06+00:00\",\"description\":\"The U.S. Food and Drug Administration (FDA) announced decisive regulatory action to restrict GLP-1 active pharmaceutical ingredients (APIs) used in non-FDA-approved compounded drugs, targeting mass-marketed alternatives to Wegovy and Ozempic by Hims & Hers and other compounding pharmacies. Concurrently, Novo Nordisk (NYSE:\u202fNVO) filed patent infringement litigation against Hims & Hers, alleging unauthorized compounded semaglutide products violate U.S. Patent 8,129,343 and mislead consumers regarding clinical benefits and safety.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56896#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56896\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56896#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement - Insight, China's Pharmaceutical Industry","description":"The U.S. Food and Drug Administration (FDA) announced decisive regulatory action to restrict GLP-1 active pharmaceutical ingredients (APIs) used in non-FDA-approved compounded drugs, targeting mass-marketed alternatives to Wegovy and Ozempic by Hims & Hers and other compounding pharmacies. Concurrently, Novo Nordisk (NYSE:\u202fNVO) filed patent infringement litigation against Hims & Hers, alleging unauthorized compounded semaglutide products violate U.S. Patent 8,129,343 and mislead consumers regarding clinical benefits and safety.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56896","og_locale":"en_US","og_type":"article","og_title":"FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement","og_description":"The U.S. Food and Drug Administration (FDA) announced decisive regulatory action to restrict GLP-1 active pharmaceutical ingredients (APIs) used in non-FDA-approved compounded drugs, targeting mass-marketed alternatives to Wegovy and Ozempic by Hims & Hers and other compounding pharmacies. Concurrently, Novo Nordisk (NYSE:\u202fNVO) filed patent infringement litigation against Hims & Hers, alleging unauthorized compounded semaglutide products violate U.S. Patent 8,129,343 and mislead consumers regarding clinical benefits and safety.","og_url":"https:\/\/flcube.com\/?p=56896","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-11T14:01:05+00:00","article_modified_time":"2026-02-11T14:01:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56896#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56896"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement","datePublished":"2026-02-11T14:01:05+00:00","dateModified":"2026-02-11T14:01:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56896"},"wordCount":420,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Hot targets","Novo Nordisk","NYSE: NVO"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56896#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56896","url":"https:\/\/flcube.com\/?p=56896","name":"FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-11T14:01:05+00:00","dateModified":"2026-02-11T14:01:06+00:00","description":"The U.S. Food and Drug Administration (FDA) announced decisive regulatory action to restrict GLP-1 active pharmaceutical ingredients (APIs) used in non-FDA-approved compounded drugs, targeting mass-marketed alternatives to Wegovy and Ozempic by Hims & Hers and other compounding pharmacies. Concurrently, Novo Nordisk (NYSE:\u202fNVO) filed patent infringement litigation against Hims & Hers, alleging unauthorized compounded semaglutide products violate U.S. Patent 8,129,343 and mislead consumers regarding clinical benefits and safety.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56896#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56896"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56896#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56896"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56896\/revisions"}],"predecessor-version":[{"id":56897,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56896\/revisions\/56897"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}